Search

BIO Celebrates 300 Biotech IPOs since Enactment of the JOBS Act

BIO CELEBRATES 300 BIOTECH IPOS SINCE ENACTMENT OF THE JOBS ACT

The biotech industry recently realized its 300 th IPO since the Jumpstart Our Business Startups Act was enacted in 2012. This marks...

Alnylam Won't Seek Quick FDA Nod For Second RNAi Drug

ALNYLAM WON'T SEEK QUICK FDA NOD FOR SECOND RNAI DRUG

A few weeks ago, Alnylam Pharmaceuticals indicated it might seek a speedy FDA approval for what could be the second-ever RNA interference...

 
 
 

SIMULTANEOUS REGULATION OF F5H IN COMT‐RNAI TRANSGENIC SWITCHGRASS ALTERS EFFECTS OF COMT SUPPRESSION ON SYRINGYL LIGNIN BIOSYNTHESIS

Plant Biotechnology Journal, Volume 0, Issue ja , -Not available-.

 
 
 
Bio Roundup: Big Approvals, ICER Influence, Drug-Price Pushback & More

BIO ROUNDUP: BIG APPROVALS, ICER INFLUENCE, DRUG-PRICE PUSHBACK & MORE

We'll start the roundup this week with two drug approvals that came late last Friday. Both were landmarks for the companies receiving...

Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More

BIO ROUNDUP: MEDICARE DRUG PRICES, FDA MOVES, GENE THERAPY NEWS & MORE

Two imminent FDA rulings on two separate drugs aren't just noteworthy for the patients they'll help, but the long and winding road...

 
 
 
Bio Roundup: Alnylam's Moment, Read on Rebates, Skinny Plans & More

BIO ROUNDUP: ALNYLAM'S MOMENT, READ ON REBATES, SKINNY PLANS & MORE

Millions of people might be on vacation as we hit the dog days, but drug makers and politicians aren't taking a break from the gamesmanship...

Agenda Posted for Xconomy's What's Hot in Boston Biotech on May 16

AGENDA POSTED FOR XCONOMY'S WHAT'S HOT IN BOSTON BIOTECH ON MAY 16

Join Xconomy next month for our sixth installment of What's Hot in Boston Biotech on May 16 at the Broad Institute of MIT and Harvard....

 
 
 
Paying for Gene Therapy, CRISPR in People, RNAi at “What's Hot” on May 16

PAYING FOR GENE THERAPY, CRISPR IN PEOPLE, RNAI AT “WHAT'S HOT” ON MAY 16

A new age of medicine is underway, and we're only just beginning to grapple with the implications. The first U.S. gene therapy , for...

A NEW REGULATOR OF CELLULASE AND XYLANASE IN THE THERMOPHILIC FUNGUS MYCELIOPHTHORA THERMOPHILA STRAIN ATCC 42464

Abstract Myceliophthora thermophila is a thermophilic fungus that produces cellulolytic enzymes with high thermal stability. Unlike...

 
 
 
LGC Acquires Lucigen, Marking Latest Exit for CEO Ralph Kauten

LGC ACQUIRES LUCIGEN, MARKING LATEST EXIT FOR CEO RALPH KAUTEN

Chalk up another exit for Ralph Kauten. Kauten, one of Wisconsin's more successful biotech entrepreneurs, is chairman and CEO of Lucigen,...

 
 
 
Eyeing a Comeback, Arrowhead Bets on New RNAi Delivery Tool

EYEING A COMEBACK, ARROWHEAD BETS ON NEW RNAI DELIVERY TOOL

Following a series of setbacks late last year, Arrowhead Pharmaceuticals, one of the companies trying to develop drugs using RNA interference,...

 
 
 
 
 
 

NANOPARTICLES FOR SIRNA-BASED GENE SILENCING IN TUMOR THERAPY

Gene silencing through RNA interference has emerged as a potential strategy in manipulating cancer causing genes by complementary base-pairing...

14 for '17: Key Clinical Data To Watch For Next Year

14 FOR '17: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR

We continue our look ahead to some of the clinical data due in 2017 that could shape healthcare practice and sway investor sentiment...

 
 
 
Arrowhead Chief Scientific Officer David Lewis Among 34 Laid Off

ARROWHEAD CHIEF SCIENTIFIC OFFICER DAVID LEWIS AMONG 34 LAID OFF

Arrowhead Pharmaceuticals has terminated the employment of chief scientific officer David Lewis, effective later this month, the company...

Alnylam Scraps RNAi Drug After Safety Problems, Shares Plunge

ALNYLAM SCRAPS RNAI DRUG AFTER SAFETY PROBLEMS, SHARES PLUNGE

Alnylam Pharmaceuticals has gone through more than a decade of twists and turns, trying to become the first company to bring an RNA...